Ozempic and Mounjaro have entered the top three pharmaceuticals for the first half of 2025. Keytruda remains the best-selling pharmaceutical, despite gains by GLP-1s, a class that includes Ozempic. The pharmaceutical landscape is expected to continue evolving, with several notable clinical trials ongoing for the rest of 2025.